This clinical trial is focused on studying the effects of a new treatment called RL-007 on individuals with schizophrenia, specifically targeting cognitive impairment associated with this condition. Schizophrenia is a mental health disorder that affects a person’s ability to think, feel, and behave clearly. Cognitive impairment refers to difficulties with memory, attention, and problem-solving skills, which are common in people with schizophrenia. The study will compare the effects of RL-007, which is taken in capsule form, to a placebo, which looks like the treatment but does not contain the active substance.

The purpose of the study is to evaluate the safety and effectiveness of RL-007 in improving cognitive performance in participants diagnosed with schizophrenia. Participants will be randomly assigned to receive either RL-007 or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will last for a period of six weeks, during which participants will take the medication orally and attend regular study visits for assessments.

Throughout the study, participants will undergo various tests to measure changes in their cognitive abilities, such as memory and attention, as well as overall health checks, including vital signs and laboratory tests. The study aims to provide valuable information on whether RL-007 can help improve cognitive function in people with schizophrenia, potentially leading to better treatment options in the future.